Floatz logo

Campath

Non-hodgkin's Lymphoma

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityPhase 2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
73/ 100

Competitive context

2 Active assets in the Non-hodgkin's Lymphoma cohort.

Asset / SponsorPhaseRating
tqb2303
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2CC
Gnc-035
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2CC
Mdx-1203
Bristol-Myers Squibb
Phase 1CC
Immu-114
Gilead Sciences
Phase 1C
cd70-targeting car-t cells
Zhejiang University
Early Phase 1C
cd4+ t cells
Masonic Cancer Center, University of Minnesota
N/AD
cd4+/cd25+ cells
Masonic Cancer Center, University of Minnesota
N/AD

Same molecule, other indications

Campath is also rated in:

sickle cell diseaseDormant
BB
Indicative ·
65 / 100
View asset →
plasma cell myelomaDormant
B
Indicative ·
62 / 100
View asset →
B-cell chronic lymphocytic leukemiaDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →